Donning a face mask is an easy way to boost protection from severe respiratory illnesses such as influenza and SARS, new research from the University of New South Wales (UNSW) has found, but convincing a reluctant public and health workers is proving a struggle.
In a world-first clinical trial of the efficacy of masks, researchers found adult mask wearers* in the home were four times more likely than non-wearers to be protected against respiratory viruses, including the common cold.
The findings, published this week in Emerging Infectious Diseases, the journal of the Centers for Disease Control and Prevention (CDC), have global implications and are particularly relevant to efforts to combat the spread of flu pandemics and other emerging respiratory diseases such as SARS.
"In the event of a severe pandemic, demand for protection could become a law and order issue," said lead author of the paper, Raina MacIntyre, professor of infectious diseases and epidemiology and head of UNSW's School of Public Health and Community Medicine.
"In a crisis, vaccine development is likely to be delayed and drugs may be in short supply or not available at all," she said. "Limited supplies will be directed first to front line health workers, so masks are an important means of protection for the community, who otherwise may be last in line for vaccines and drugs."
While some governments are already stockpiling masks for use in emergencies, MacIntyre said these guidelines had been implemented without evidence to support them. "We now have provided that evidence. Masks play an important role in reducing transmission if they are worn properly."
At a day-to-day level, the study is also good news for parents of toddlers and young children.
"There is no effective treatment for the 90 or so common cold viruses that make families sick each winter, but masks could provide simple and effective protection," MacIntyre said.
Commissioned and funded by the Australian Department of Health and Ageing in response to an urgent policy need, the study is the first randomized controlled clinical trial of masks to be conducted internationally. Researchers at UNSW, Sydney's WestmeadHospital, ImperialCollege (London) and the National Centre for Immunization Research studied more than 280 adults in 143 families in Sydney during the winter seasons of 2006 and 2007. The adults were randomly allocated masks when exposed to a sick child in the household.
MacIntyre said a drawback was participants' low compliance, with less than half reporting having worn the masks often or always. However, adherence to preventive measures is known to vary depending on perception of risk and would be expected to increase during a pandemic.
The next pressing research question is the value of the use of masks among health care workers. Preliminary work in Australia in 2007 showed very low acceptance of and compliance with mask use by hospital doctors and nurses.
MacIntyre and her team, along with the Beijing Centers for Disease Control and Prevention, are now running a large trial of masks in close to 2,000 healthcare workers in more than 20 hospitals in China, where compliance with masks is much greater.
"Results from this trial could have wide implications for not only pandemic influenza, but a range of communicable diseases spread within hospitals,” MacIntyre said.
* both surgical and non-fit-tested P2 masks
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.